首页> 外文期刊>Experimental parasitology >Fasciola gigantica and Schistosoma mansoni: vaccine potential of recombinant glutathione S-transferase (rFgGST26) against infections in mice.
【24h】

Fasciola gigantica and Schistosoma mansoni: vaccine potential of recombinant glutathione S-transferase (rFgGST26) against infections in mice.

机译:巨大的Fasciola and mansoni血吸虫:重组谷胱甘肽S转移酶(rFgGST26)对小鼠感染的疫苗潜力。

获取原文
获取原文并翻译 | 示例
       

摘要

Recombinant Fasciola gigantica glutathione S-transferase (rFgGST26) was expressed in Escherichia coli. This protein had 86% and 56% sequence identity with 26 kDa GST from Fasciola hepatica and Schistosoma mansoni, respectively. Polyclonal antibody raised in ICR mice against rFgGST26 recognized immunoblotted 26 kDa native GSTs from F. gigantica and S. mansoni. rFgGST26 was used as a vaccine in combination with Freund's adjuvant to evaluate the induction of immune responses and protection against F. gigantica and S. mansoni infection in mice. Mice were immunized via subcutaneous (s.c.), intramuscular (i.m.) or intradermal (i.d.) routes. Strong protection (77-84%) against F. gigantica was observed in all routes. Immunization via s.c. route induced immune response with IgG1 isotype predominating, while i.m. and i.d. routes resulted in mixed IgG1/IgG2a immune responses. Passive intraperitoneal transfer of IgG1 predominating antisera from s.c. rFgGST26-immunized donors to naive recipient mice resulted in 47% protection against F. gigantica infection. This suggests that the mechanism of resistance depends on the presence of specific antibody against rFgGST26. Immunization with rFgGST26 via i.m. and i.d. routes resulted in significant cross protection (55%) against S. mansoni infection in the i.d. route with mixed IgG1/IgG2a response with IgG1 isotype predominating. This indicated that rFgGST26 is a good vaccine candidate against F. gigantica in mice and could also provide cross protection against S. mansoni.
机译:重组费舍拉谷胱甘肽谷胱甘肽S-转移酶(rFgGST26)在大肠杆菌中表达。该蛋白与来自肝片吸虫和曼氏血吸虫的26 kDa GST分别具有86%和56%的序列同一性。在ICR小鼠中产生的针对rFgGST26的多克隆抗体可识别来自F. gigantica和S. mansoni的免疫印迹26 kDa天然GST。 rFgGST26与弗氏佐剂一起用作疫苗,以评估免疫应答的诱导以及对小鼠巨大巨球藻和曼氏沙门氏菌感染的保护作用。通过皮下(s.c.),肌内(i.m.)或皮内(i.d.)途径免疫小鼠。在所有途径中均观察到针对巨巨镰刀菌的强力保护(77-84%)。通过s.c.免疫途径以IgG1同种型为主的诱导免疫应答,而i.m.和我这些途径导致混合的IgG1 / IgG2a免疫反应。 IgG1的被动腹膜内转移主要来自皮下。幼稚受体小鼠的rFgGST26免疫供体导致针对巨巨球菌感染的保护率为47%。这表明抗药性的机制取决于针对rFgGST26的特异性抗体的存在。通过i.m.使用rFgGST26免疫。和我这些途径导致了对曼氏沙门氏菌感染的显着交叉保护(55%)。混合的IgG1 / IgG2a反应途径,以IgG1同种型为主。这表明rFgGST26是小鼠抗巨大链球菌的良好候选疫苗,还可以提供针对曼氏链球菌的交叉保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号